Immatics Earnings Reports

Immatics' Q2 2025 revenue fell year-over-year as milestone income declined, while R&D investments increased to support PRAME clinical programs. The company retains over $560M in cash and continues progressing multiple pipeline assets across trials.

Immatics reported a significant increase in net loss for Q1 2025 compared to the same period last year, primarily due to lower revenue from collaboration agreements and unrealized foreign exchange losses. The company continues to advance its clinical pipeline, particularly the SUPRAME Phase 3 trial for IMA203, and maintains a strong cash position.